Research compounds
SR9009
Stenabolic
SR9009 is a REV-ERB agonist marketed as an endurance and fat-loss compound. It is a small molecule, not a SARM and not a peptide, and its oral bioavailability is so poor that the basis for oral use is doubtful.
Also known as: SR-9009, SR 9009
- Status
- SR9009 is a research compound and not approved by the FDA for human use.
- Evidence
- Preclinical. Evidence comes from animal or lab studies; effects in people are not established.
- Half-life
- Approximately 1 hour, requiring frequent dosing.
- How it's taken
- Oral in non-clinical use, despite poor oral bioavailability
- Mechanism
- Metabolic (non-incretin)
- Pathways
- Mitochondrial
How SR9009 works
SR9009 is a synthetic agonist of the REV-ERB nuclear receptors, which are core components of the circadian clock and also regulate lipid and glucose metabolism and mitochondrial biogenesis. In mice, injected SR9009 increased mitochondrial content in skeletal muscle and improved running endurance, and altered circadian behaviour.
What research has looked at
- The mouse endurance and mitochondrial biogenesis findings are real published results and are the origin of its reputation.
- REV-ERB is a legitimate and interesting target linking circadian biology to metabolism.
- It has no androgen receptor activity, so unlike the SARMs it carries no expectation of testosterone suppression.
Evidence level: Preclinical. Evidence comes from animal or lab studies; effects in people are not established. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Its oral bioavailability in rodents is very low — reported at a few percent — and the mouse studies used intraperitoneal injection. The compound is sold and taken orally, which is unlikely to reproduce the effects claimed for it.
- There are no human trials of any kind, and no regulator has approved it. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Subsequent work has questioned whether some SR9009 effects are REV-ERB-mediated at all, since they persist in REV-ERB knockout cells — meaning the compound has significant off-target activity that is not characterised.
- Manipulating the circadian clock pharmacologically has unknown long-term consequences.
- Prohibited at all times under the WADA Prohibited List.
Sources
- PubMed research on SR9009 REV-ERB bioavailability off-target · NIH · National Library of Medicine
- DrugBank record for SR9009 · DrugBank
- Active clinical trials for SR9009 · U.S. National Library of Medicine
Track SR9009 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
SR9009 FAQ
What is SR9009?
SR9009 is a REV-ERB agonist marketed as an endurance and fat-loss compound. It is a small molecule, not a SARM and not a peptide, and its oral bioavailability is so poor that the basis for oral use is doubtful.
How does SR9009 work?
SR9009 is a synthetic agonist of the REV-ERB nuclear receptors, which are core components of the circadian clock and also regulate lipid and glucose metabolism and mitochondrial biogenesis. In mice, injected SR9009 increased mitochondrial content in skeletal muscle and improved running endurance, and altered circadian behaviour.
Is SR9009 FDA approved?
No. SR9009 is a research compound and not approved by the FDA for human use. Evidence level: preclinical. Evidence comes from animal or lab studies; effects in people are not established.
What is the half-life of SR9009?
Reported half-life: Approximately 1 hour, requiring frequent dosing.
How is SR9009 taken?
Oral in non-clinical use, despite poor oral bioavailability.
What side effects have been reported with SR9009?
Reported in the sources: Its oral bioavailability in rodents is very low — reported at a few percent — and the mouse studies used intraperitoneal injection. The compound is sold and taken orally, which is unlikely to reproduce the effects claimed for it; There are no human trials of any kind, and no regulator has approved it. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; Subsequent work has questioned whether some SR9009 effects are REV-ERB-mediated at all, since they persist in REV-ERB knockout cells — meaning the compound has significant off-target activity that is not characterised; Manipulating the circadian clock pharmacologically has unknown long-term consequences; Prohibited at all times under the WADA Prohibited List.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.